Physical: Weight and T skin color, lesions orientation, affect, reflexes ophthalmic examination P, BP, R, adventitious sounds bowel sounds, normal output normal fluid intake, normal output, voiding pattern thyroid, renal glomerular and tubular function tests, urinalysis, CBC and differential, baseline ECG.History: Hypersensitivity to tartrazine significant renal or CV disease severe debilitation, dehydration sodium depletion, patients on diuretics protracted sweating, diarrhea suicidal or impulsive patients infection with fever pregnancy lactation.Severe renal and cardiac disease severe dehydration, sodium depletion, debilitation.
Potentially Fatal: Severe neurotoxicity, leucopenia.Exacerbation of psoriasis, acne, rash nausea, diarrhoea, vertigo, muscle weakness, dazed feeling loss of concentration tremors hypothyroidism wt gain, oedema cardiac arrhythmias exophthalmos restlessness electrolyte disturbances.Unlabeled use: Improvement of neutrophil counts in patients with cancer chemotherapy–induced neutropenia and in children with chronic neutropenia and HIV patients on zidovudine therapy (doses of 300–1,000 mg/day, serum levels of 0.5 and 1 mEq/L) prophylaxis of cluster headache and cyclic migraine headache, treatment of SIADH, hypothyroidism (doses of 600–900 mg/day).Treatment of manic episodes of manic-depressive illness maintenance therapy to prevent or diminish frequency and intensity of subsequent manic episodes.Lithium’s exact mechanism is unclear but it alters intraneuronal metabolism of catecholamines and sodium transport in neurons and muscle cells.Plasma half-life is prolonged in renal impairment. Elderly patients often respond to reduced dosage and may exhibit signs of toxicity at serum levels tolerated by other patients. GERIATRIC PATIENTS AND PATIENTS WITH RENAL IMPAIRMENT Safety and efficacy for children Conversion from conventional to slow-release dosage forms: Give the same total daily dose divided into two or three doses.Serum levels should be determined at least every 2 mo in samples drawn immediately before a dose (at least 8–12 hr after previous dose). Long-term use: 300 mg PO tid–qid to produce a serum level of 0.6–1.2 mEq/L.Serum levels should be determined twice per wk in samples drawn immediately before a dose (at least 8–12 hr after previous dose). Acute mania: 600 mg PO tid or 900 mg slow-release form PO bid to produce effective serum levels between 1 and 1.5 mEq/L.Pregnancy Category D Dosage & Route ADULTS
Generic Name : lithium, lithium carbonate, lithium citrateīrand Name: Carbolith (CAN), Duralith (CAN), Eskalith, Eskalith CR, Lithane (CAN), Lithobid, Lithonate, Lithotabs, PMS-Lithium Carbonate (CAN)
0 kommentar(er)
